Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
Pliant Therapeutics director Gayle A. Crowell received a compensation grant of stock options. The award covers 70,000 options to buy Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the options vest on October 1, 2026, another 25% on January 1, 2027, and another 25% on April 1, 2027. The remaining 25% vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to Crowell’s continued service as a director.
Pliant Therapeutics director Thomas A. McCourt received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $1.14 per share and expire on June 11, 2036.
These options were granted as compensation and do not represent an open-market purchase. According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to McCourt’s continued service on the board.
Pliant Therapeutics director Steve E. Krognes received a compensation-related stock option grant. He was awarded options to purchase 70,000 shares of Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the option vests and becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, provided he continues to serve as a director through the applicable dates.
Pliant Therapeutics director John T. Curnutte received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036, giving him the right to buy shares at that price in the future.
According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, subject to his continued service as a director.
PLIANT THERAPEUTICS director Hoyoung Huh received a new stock option grant for 70,000 shares of common stock. The option has a $1.14 per share exercise price and expires on June 11, 2036. This is a compensation-related award, not an open-market trade.
According to the vesting schedule, 25% of the option becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, contingent on continued board service.
PLIANT THERAPEUTICS, INC. director Darren S. Cline received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036.
These options were granted as compensation rather than bought in the open market. According to the vesting schedule, 25% of the options vest and become exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds options for 70,000 shares directly.
Pliant Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 15, 2026 record date, 61,914,664 shares of common stock were outstanding and entitled to vote.
Stockholders elected Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Pliant Therapeutics reported a much smaller net loss of $20.0 million for the quarter ended March 31, 2026, compared with $56.2 million a year earlier, as it completed restructuring and shifted focus to oncology. Operating expenses fell sharply, with research and development down to $13.6 million and general and administrative to $8.2 million.
The company ended the quarter with $172.4 million in cash, cash equivalents, restricted cash and short-term investments and no outstanding debt, and believes this will fund operations for at least the next 12 months and beyond. Pliant is now centered on its integrin-based solid tumor program, PLN‑101095, with a Phase 1b FORTIFY trial enrolling and updated Phase 1 data showing anti-tumor activity in combination with pembrolizumab.
Pliant Therapeutics reported first quarter 2026 results and highlighted progress in its oncology and delivery platforms. The company’s lead program, PLN-101095, advanced with first patient dosed in FORTIFY, a Phase 1b indication expansion trial in checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027.
Updated Phase 1 data for PLN-101095 presented at AACR 2026 showed one confirmed complete response, two confirmed partial responses and one unconfirmed partial response in heavily pretreated patients, with biomarker changes consistent with enhanced immune activity and a generally well tolerated safety profile. Pliant is also advancing an integrin-targeted delivery platform for tissue-specific siRNA delivery.
Financially, first quarter 2026 research and development expenses were $13.6 million and general and administrative expenses were $8.2 million, both sharply lower than the prior-year period. Net loss narrowed to $20.0 million, or $0.32 per share, and the company ended March 31, 2026 with $172.4 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2028.